Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial with docetaxel and gemcitabine in hormone-refractory prostate cancer
2004-002353-31Phase 2Completed
- Sponsor
- Organisation name was not entered
- Start
- Jul 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in prostate cancer (PCa), sponsored by Organisation name was not entered. Primary endpoints: Recommended phase II dose determination and Phase II primary endpoint (unspecified). Started Jul 2008; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-002353-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002353-31.